Wafik El-Deiry, former Associate Dean for Oncologic Sciences and Founding Director of the Cancer Center at Brown University, shared on LinkedIn:
“Aspirin does not prevent recurrence after curative treatment of colorectal cancer liver metastases (phase 3 ASAC).
Lancet Gastroenterology & Hepatology · Nov 2 · Negative trial
‘We found no benefit from aspirin in preventing cancer recurrence in these patients.’
466 patients at 14 Nordic hospitals, aspirin 160 mg daily vs placebo for up to 3 years.
No reduction in recurrence; overall survival was lower and serious adverse events more common with aspirin (the authors urge caution in reading the survival finding).”
You can also read:
EMT2 at ESMO 2026: Eicosapentaenoic Acid After Colorectal Cancer Liver Metastasis Resection
